Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,814 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky AJ, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson TW, Vlachojannis GJ, Arkenbout KE, Holmvang L, Janssens L, Brugaletta S, Naber CK, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina CM, Buszman PE, Thiele H, Schächinger V, Wijns W. Lansky AJ, et al. Among authors: zheng m. EuroIntervention. 2023 Dec 4;19(10):e844-e855. doi: 10.4244/EIJ-D-23-00409. EuroIntervention. 2023. PMID: 37860860 Free article. Clinical Trial.
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers.
Baumbach A, Lansky AJ, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zheng M, Van Royen N, Slagboom T, Vlachojannis G, Xu B, Serruys PW, Wijns W. Baumbach A, et al. Among authors: zheng m. EuroIntervention. 2018 Nov 20;14(10):1121-1128. doi: 10.4244/EIJ-D-18-00226. EuroIntervention. 2018. PMID: 29901441 Free article. Clinical Trial.
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A; TARGET All Comers Investigators. Lansky A, et al. Among authors: zheng m. Lancet. 2018 Sep 29;392(10153):1117-1126. doi: 10.1016/S0140-6736(18)31649-0. Epub 2018 Sep 3. Lancet. 2018. PMID: 30190206 Clinical Trial.
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W; TARGET AC Investigators. Xu B, et al. Among authors: zheng m. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1679-1687. doi: 10.1016/j.jcin.2019.05.001. Epub 2019 May 22. JACC Cardiovasc Interv. 2019. PMID: 31129092 Free article. Clinical Trial.
Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent.
Saito Y, Baumbach A, Wijns W, Xu B, Kelbaek H, Zheng M, Morel MA, Anderson R, Schächinger V, Lansky A; TARGET AC Investigators. Saito Y, et al. Among authors: zheng m. Catheter Cardiovasc Interv. 2020 Nov;96(5):1023-1028. doi: 10.1002/ccd.28609. Epub 2019 Nov 25. Catheter Cardiovasc Interv. 2020. PMID: 31769161 Clinical Trial.
Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial.
Saito Y, Kelbæk H, Xu B, Hussain Y, Anderson R, Schächinger V, Zheng M, Wijns W, Baumbach A, Lansky AJ. Saito Y, et al. Among authors: zheng m. EuroIntervention. 2021 Jul 20;17(4):e332-e334. doi: 10.4244/EIJ-D-20-00344. EuroIntervention. 2021. PMID: 32482617 Free PMC article. No abstract available.
Differential impact of abluminal groove-filled biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent on and off dual antiplatelet therapy.
Saito Y, Wijns W, Baumbach A, Xu B, Kelbaek H, Zheng M, Morel MA, Anderson R, Schächinger V, Lansky A; TARGET AC Investigators. Saito Y, et al. Among authors: zheng m. Catheter Cardiovasc Interv. 2022 Feb;99(2):357-365. doi: 10.1002/ccd.29468. Epub 2021 Jan 27. Catheter Cardiovasc Interv. 2022. PMID: 33502809 Clinical Trial.
Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial.
Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, Su X, Ma Y, Zhang Q, Liu J, Wang Y, Guan C, Zheng M, Qiao S, Gao R; FUTURE-II Trial Investigators. Song L, et al. Among authors: zheng m. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1450-1462. doi: 10.1016/j.jcin.2021.04.048. Epub 2021 May 18. JACC Cardiovasc Interv. 2021. PMID: 34238555 Free article. Clinical Trial.
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Yang H, et al. Among authors: zheng m. BMJ Open. 2019 Dec 17;9(12):e033774. doi: 10.1136/bmjopen-2019-033774. BMJ Open. 2019. PMID: 31852711 Free PMC article.
8,814 results